Meng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meng Wang has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Hao Chen
Department of General Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China
8 shared publicationsLiang Tao
Department of Gastric Surgery, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China
5 shared publications- Liang Tao
Division of Gastric Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
5 shared publications Lianlian Cao
Department of Gastric Surgery, Drum Tower Clinical Medical College, Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China
5 shared publicationsLinsen Bao
Division of Gastric Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
5 shared publicationsZhaoping Li
Department of Gastric Surgery, Drum Tower Clinical Medical College, Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China
5 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
The optimal time of additional surgery after non-curative endoscopic submucosal dissection in eCura-C2 gastric cancer patients
- 25 September 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Open AccessThe optimal time of additional surgery after non-curative endoscopic submucosal dissection in eCura-C2 gastric cancer patients
- Open Access
- 27 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Recurrence‑related factors after discontinuation of adjuvant imatinib in intermediate‑ and high‑risk GIST: a retrospective cohort study
- 27 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessRecurrence‑related factors after discontinuation of adjuvant imatinib in intermediate‑ and high‑risk GIST: a retrospective cohort study
- Open Access
- 27 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e82712
Tunnel Anastomosis vs Double-Tract Jejunal Interposition Reconstruction After Proximal Gastrectomy: Protocol for a Multicenter Prospective Randomized Controlled Trial
Background: Tunnel anastomosis is a novel anastomotic technique for digestive tract reconstruction following proximal gastrectomy. A previous retrospective study by our team demonstrated its favorable antireflux effect; therefore, we hypothesize that tunnel anastomosis is noninferior to double-tract jejunal interposition reconstruction in preventing postoperative reflux esophagitis, and we will conduct this prospective study to further validate this assumption. Objective: In this study, we will prospectively compare tunnel anastomosis with the currently more prevalent double-tract jejunal interposition reconstruction technique to further validate its safety and efficacy. Methods: This is a multicenter prospective randomized controlled study that will enroll 240 patients who will undergo proximal gastrectomy. The study will be divided into 2 groups: the tunnel anastomosis group and the double-tract jejunal interposition reconstruction group, with 120 patients in each group. Patients will undergo clinical assessments and complete questionnaires preoperatively, as well as at the 3rd, 6th, and 12th months postoperatively. The primary end point is the incidence of reflux esophagitis within 1 year. The secondary end points include perioperative safety, postoperative quality of life, and postoperative nutritional status. Results: Recruitment of patients commenced in March 2022 and is scheduled to conclude in February 2027. The follow-up for all enrolled patients will be completed by February 2028. Conclusions: To our knowledge, this is the first prospective study on this technique, aiming to provide novel insights into the methods of digestive reconstruction following proximal gastrectomy.
- 27 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e82712
Open AccessTunnel Anastomosis vs Double-Tract Jejunal Interposition Reconstruction After Proximal Gastrectomy: Protocol for a Multicenter Prospective Randomized Controlled Trial
Background: Tunnel anastomosis is a novel anastomotic technique for digestive tract reconstruction following proximal gastrectomy. A previous retrospective study by our team demonstrated its favorable antireflux effect; therefore, we hypothesize that tunnel anastomosis is noninferior to double-tract jejunal interposition reconstruction in preventing postoperative reflux esophagitis, and we will conduct this prospective study to further validate this assumption. Objective: In this study, we will prospectively compare tunnel anastomosis with the currently more prevalent double-tract jejunal interposition reconstruction technique to further validate its safety and efficacy. Methods: This is a multicenter prospective randomized controlled study that will enroll 240 patients who will undergo proximal gastrectomy. The study will be divided into 2 groups: the tunnel anastomosis group and the double-tract jejunal interposition reconstruction group, with 120 patients in each group. Patients will undergo clinical assessments and complete questionnaires preoperatively, as well as at the 3rd, 6th, and 12th months postoperatively. The primary end point is the incidence of reflux esophagitis within 1 year. The secondary end points include perioperative safety, postoperative quality of life, and postoperative nutritional status. Results: Recruitment of patients commenced in March 2022 and is scheduled to conclude in February 2027. The follow-up for all enrolled patients will be completed by February 2028. Conclusions: To our knowledge, this is the first prospective study on this technique, aiming to provide novel insights into the methods of digestive reconstruction following proximal gastrectomy.
- Open Access
- 23 February 2026
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (8) , 101758
Disturbance of Oxylipin Metabolism Mediated by Autophagy of Mesenteric Adipocytes Orchestrates Gut Inflammation in Crohn’s Disease
- 23 February 2026
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (8) , 101758
Open AccessDisturbance of Oxylipin Metabolism Mediated by Autophagy of Mesenteric Adipocytes Orchestrates Gut Inflammation in Crohn’s Disease
- 5 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (4) , 813-830
PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma
Deubiquitinases (DUBs) are pivotal in cancer progression, yet their role in metabolic reprogramming in gastric adenocarcinoma (GAC) remains unclear. Here, we discover that highly expressed PSMD14 strengthens tumor stemness and drives tumor progression by increasing glycolysis and lactate accumulation, which activates H3K27 lactylation (H3K27la) and turns to enhance the expression of PSMD14 and SOX9. Mechanistically, PSMD14 deubiquitinates PFKFB2 at K355, facilitating SCYL2-mediated phosphorylation of PFKFB2 at S466/S483, which increases the generation of fructose-2,6-bisphosphate, activating PFK1 and glycolysis. Additionally, the H3K27la/PSMD14/SCYL2/p-PFKFB2 axis correlates with increased glucose metabolic activity and poor prognosis in GAC patients. Notably, high-throughput screening of FDA-approved drugs reveals that Daclatasvir (DCV) exhibits high binding affinity for PSMD14 protein, disrupts the PSMD14-PFKFB2 interaction, reduces PFKFB2 activity and tumor burden. Collectively, our findings are the first to elucidate a positive feedback loop existing between PSMD14 and glycolysis in GAC progression, suggesting that PSMD14 blockade may represent a potential therapeutic approach for GAC.
- 5 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (4) , 813-830
PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma
Deubiquitinases (DUBs) are pivotal in cancer progression, yet their role in metabolic reprogramming in gastric adenocarcinoma (GAC) remains unclear. Here, we discover that highly expressed PSMD14 strengthens tumor stemness and drives tumor progression by increasing glycolysis and lactate accumulation, which activates H3K27 lactylation (H3K27la) and turns to enhance the expression of PSMD14 and SOX9. Mechanistically, PSMD14 deubiquitinates PFKFB2 at K355, facilitating SCYL2-mediated phosphorylation of PFKFB2 at S466/S483, which increases the generation of fructose-2,6-bisphosphate, activating PFK1 and glycolysis. Additionally, the H3K27la/PSMD14/SCYL2/p-PFKFB2 axis correlates with increased glucose metabolic activity and poor prognosis in GAC patients. Notably, high-throughput screening of FDA-approved drugs reveals that Daclatasvir (DCV) exhibits high binding affinity for PSMD14 protein, disrupts the PSMD14-PFKFB2 interaction, reduces PFKFB2 activity and tumor burden. Collectively, our findings are the first to elucidate a positive feedback loop existing between PSMD14 and glycolysis in GAC progression, suggesting that PSMD14 blockade may represent a potential therapeutic approach for GAC.
- Open Access
- 1 July 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-15
Inflammatory and nutritional markers predict response and prognosis of patients with locally advanced gastric cancer receiving neoadjuvant immunochemotherapy
Metabolism plays an important role in the occurrence and development of gastric cancer, including in neoadjuvant immunochemotherapy. However, whether nutrition-related indicators can predict the efficacy of neoadjuvant immunochemotherapy and the prognosis of gastric cancer patients has not been addressed. This study systematically screens various nutritional indicators to explore their efficacy in predicting responses to neoadjuvant immunochemotherapy and patients’ prognosis in locally advanced gastric cancer (LAGC). We retrospectively analyzed 134 LAGC patients who underwent radical resection after neoadjuvant immunochemotherapy. According to postoperative tumor regression grade (TRG), these patients were divided into good responder group (TRG1-0) and poor responder group (TRG3-2) (AJCC/CAP guidelines). Inflammatory and/or nutritional markers were compared for their efficacy on predicting patients’ pathological tumor regression response. The univariate and multivariate logistic regression were carried out to identify the independent factors for predicting pathological tumor regression response, and a predictive nomogram model was further established. Among the total 134 LAGC patients, tumor specimens from 71 and 63 patients had TRG1-0 and TRG3-2 tumor responses, respectively. Multivariate analysis showed that controlling nutritional status (CONUT) score and nutrition risk screening 2002 (NRS2002) score were independent predictors of pathological tumor regression response (OR, 0.68; 95% CI, 0.50–0.91; P = 0.010 and OR, 0.66; 95% CI, 0.45–0.96; P = 0.031, respectively). With the use of ROC curve analysis, the optimal critical level of CONUT score and NRS2002 score were both 3. The CONUT-NRS2002 combined score was constructed. Patients with lower CONUT-NRS2002 had a better pathological response than those with higher CONUT-NRS2002 (P = 0.003). Moreover, Patients with higher CONUT-NRS2002 scores had poorer prognosis (P < 0.05). The nomogram based on CONUT score and NRS2002 score demonstrated good predictive ability and clinical application value. CONUT score and NRS2002 score are independent factors of pathological tumor regression response in LAGC patients after neoadjuvant immunochemotherapy. The constructed CONUT-NRS2002 combined score has a good potential in predicting pathological tumor regression response and prognosis of LAGC patients after neoadjuvant immunochemotherapy, serving as a new predictive indicator.
- 1 July 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-15
Open AccessInflammatory and nutritional markers predict response and prognosis of patients with locally advanced gastric cancer receiving neoadjuvant immunochemotherapy
Metabolism plays an important role in the occurrence and development of gastric cancer, including in neoadjuvant immunochemotherapy. However, whether nutrition-related indicators can predict the efficacy of neoadjuvant immunochemotherapy and the prognosis of gastric cancer patients has not been addressed. This study systematically screens various nutritional indicators to explore their efficacy in predicting responses to neoadjuvant immunochemotherapy and patients’ prognosis in locally advanced gastric cancer (LAGC). We retrospectively analyzed 134 LAGC patients who underwent radical resection after neoadjuvant immunochemotherapy. According to postoperative tumor regression grade (TRG), these patients were divided into good responder group (TRG1-0) and poor responder group (TRG3-2) (AJCC/CAP guidelines). Inflammatory and/or nutritional markers were compared for their efficacy on predicting patients’ pathological tumor regression response. The univariate and multivariate logistic regression were carried out to identify the independent factors for predicting pathological tumor regression response, and a predictive nomogram model was further established. Among the total 134 LAGC patients, tumor specimens from 71 and 63 patients had TRG1-0 and TRG3-2 tumor responses, respectively. Multivariate analysis showed that controlling nutritional status (CONUT) score and nutrition risk screening 2002 (NRS2002) score were independent predictors of pathological tumor regression response (OR, 0.68; 95% CI, 0.50–0.91; P = 0.010 and OR, 0.66; 95% CI, 0.45–0.96; P = 0.031, respectively). With the use of ROC curve analysis, the optimal critical level of CONUT score and NRS2002 score were both 3. The CONUT-NRS2002 combined score was constructed. Patients with lower CONUT-NRS2002 had a better pathological response than those with higher CONUT-NRS2002 (P = 0.003). Moreover, Patients with higher CONUT-NRS2002 scores had poorer prognosis (P < 0.05). The nomogram based on CONUT score and NRS2002 score demonstrated good predictive ability and clinical application value. CONUT score and NRS2002 score are independent factors of pathological tumor regression response in LAGC patients after neoadjuvant immunochemotherapy. The constructed CONUT-NRS2002 combined score has a good potential in predicting pathological tumor regression response and prognosis of LAGC patients after neoadjuvant immunochemotherapy, serving as a new predictive indicator.
- Open Access
- 16 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-15
Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis
Sorafenib is the main treatment for advanced hepatocellular carcinoma (HCC), but drug resistance limits its effectiveness. Evidence increasingly indicates that, in addition to targeting tyrosine kinases, sorafenib also induces ferroptosis. However, current studies have not fully clarified the relationship between ferroptosis and sorafenib treatment sensitivity. Our bioinformatics analysis identified that SIX Homeobox 2 (SIX2), known for maintaining cellular stemness via the Wnt signaling pathway, was significantly upregulated in sorafenib-resistant tissues. Overexpression and knockdown experiments revealed that altering SIX2 expression affected HCC cell sensitivity to sorafenib and involved the ferroptosis pathway, suggesting a regulatory role for SIX2 in ferroptosis. RNA sequencing and CUT&Tag analysis showed that SIX2 directly regulated methyltransferase 9 (METTL9) expression. Co-immunoprecipitation (Co-IP) assays confirmed that METTL9 bound to SLC7A11, enhancing its stability and reducing degradation, thus regulating ferroptosis. Importantly, the role of SIX2 in ferroptosis operated independently of the classical glutathione peroxidase 4 (GPX4) pathway. In vitro studies further supported these findings, demonstrating that SIX2 knockdown increased sorafenib-induced ferroptosis in HCC, while METTL9 overexpression largely counteracted the effects of SIX2 knockdown. In mouse models, overexpression of SIX2 increased tumor resistance to sorafenib. Our findings suggest that modulating the ferroptosis pathway through SIX2 could enhance sorafenib sensitivity. This study provides the first evidence that SIX2 influences ferroptosis via the METTL9-SLC7A11 axis, thereby sensitizing HCC cells to sorafenib. Reducing SIX2 expression could thus represent a promising strategy to improve the efficacy of sorafenib in advanced HCC.
- 16 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-15
Open AccessTargeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis
Sorafenib is the main treatment for advanced hepatocellular carcinoma (HCC), but drug resistance limits its effectiveness. Evidence increasingly indicates that, in addition to targeting tyrosine kinases, sorafenib also induces ferroptosis. However, current studies have not fully clarified the relationship between ferroptosis and sorafenib treatment sensitivity. Our bioinformatics analysis identified that SIX Homeobox 2 (SIX2), known for maintaining cellular stemness via the Wnt signaling pathway, was significantly upregulated in sorafenib-resistant tissues. Overexpression and knockdown experiments revealed that altering SIX2 expression affected HCC cell sensitivity to sorafenib and involved the ferroptosis pathway, suggesting a regulatory role for SIX2 in ferroptosis. RNA sequencing and CUT&Tag analysis showed that SIX2 directly regulated methyltransferase 9 (METTL9) expression. Co-immunoprecipitation (Co-IP) assays confirmed that METTL9 bound to SLC7A11, enhancing its stability and reducing degradation, thus regulating ferroptosis. Importantly, the role of SIX2 in ferroptosis operated independently of the classical glutathione peroxidase 4 (GPX4) pathway. In vitro studies further supported these findings, demonstrating that SIX2 knockdown increased sorafenib-induced ferroptosis in HCC, while METTL9 overexpression largely counteracted the effects of SIX2 knockdown. In mouse models, overexpression of SIX2 increased tumor resistance to sorafenib. Our findings suggest that modulating the ferroptosis pathway through SIX2 could enhance sorafenib sensitivity. This study provides the first evidence that SIX2 influences ferroptosis via the METTL9-SLC7A11 axis, thereby sensitizing HCC cells to sorafenib. Reducing SIX2 expression could thus represent a promising strategy to improve the efficacy of sorafenib in advanced HCC.
- 16 June 2025
- Published by Springer Nature in Oncogene
- p. 1-13
NNMT-mediated N6-methyladenosine modification of NR4A3 mRNA facilitates lymphatic metastasis of gastric adenocarcinoma
Lymph node (LN) metastasis is a common feature of gastric adenocarcinoma (GAC) and is closely associated with a poor prognosis. Our previous study highlighted the pivotal role of nicotinamide N-methyltransferase (NNMT) in driving GAC carcinogenesis and malignant progression, primarily through its regulation of histone methylation. However, the mechanisms by which NNMT contributes to LN metastasis in GAC remain poorly understood. In this study, we demonstrated that elevated NNMT expression was positively correlated with LN metastasis and a poor prognosis in GAC patients. Gain- and loss-of-function experiments further revealed that NNMT accelerated GAC-related lymphangiogenesis, migration, and invasion in vitro and facilitated LN metastasis in vivo. Mechanistically, NNMT promoted the degradation of NR4A3 mRNA by diminishing its m6A methylation, which diminished the binding of NR4A3 protein to the promoters of fibroblast growth factor 2 (FGF2) and hepatocyte growth factor (HGF), leading to increased expression of FGF2 and HGF, which in turn enhanced lymphangiogenesis and facilitated lymphatic metastasis in GAC. Collectively, our findings suggest that NNMT plays an oncogenic role in GAC and may serve as a valuable prognostic biomarker and therapeutic target for treating LN-metastatic GAC. NNMT promotes NR4A3 mRNA degradation by diminishing its m6A methylation, consequently promoting lymphangiogenesis and lymphatic metastasis in GAC.
- 16 June 2025
- Published by Springer Nature in Oncogene
- p. 1-13
NNMT-mediated N6-methyladenosine modification of NR4A3 mRNA facilitates lymphatic metastasis of gastric adenocarcinoma
Lymph node (LN) metastasis is a common feature of gastric adenocarcinoma (GAC) and is closely associated with a poor prognosis. Our previous study highlighted the pivotal role of nicotinamide N-methyltransferase (NNMT) in driving GAC carcinogenesis and malignant progression, primarily through its regulation of histone methylation. However, the mechanisms by which NNMT contributes to LN metastasis in GAC remain poorly understood. In this study, we demonstrated that elevated NNMT expression was positively correlated with LN metastasis and a poor prognosis in GAC patients. Gain- and loss-of-function experiments further revealed that NNMT accelerated GAC-related lymphangiogenesis, migration, and invasion in vitro and facilitated LN metastasis in vivo. Mechanistically, NNMT promoted the degradation of NR4A3 mRNA by diminishing its m6A methylation, which diminished the binding of NR4A3 protein to the promoters of fibroblast growth factor 2 (FGF2) and hepatocyte growth factor (HGF), leading to increased expression of FGF2 and HGF, which in turn enhanced lymphangiogenesis and facilitated lymphatic metastasis in GAC. Collectively, our findings suggest that NNMT plays an oncogenic role in GAC and may serve as a valuable prognostic biomarker and therapeutic target for treating LN-metastatic GAC. NNMT promotes NR4A3 mRNA degradation by diminishing its m6A methylation, consequently promoting lymphangiogenesis and lymphatic metastasis in GAC.
- 21 April 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (7) , 102066
Effects of perioperative ω-3 fish oil fat emulsion on postoperative gastric emptying function following Roux-en-Y reconstruction for gastric cancer
- 21 April 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (7) , 102066
Effects of perioperative ω-3 fish oil fat emulsion on postoperative gastric emptying function following Roux-en-Y reconstruction for gastric cancer
- Open Access
- 30 March 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-10
Pancreatic atrophy after gastric cancer surgery: influencing factors and effects on BMI and quality of life
Pancreatic atrophy can occur after gastric cancer surgery, but the influencing factors and effects of pancreatic atrophy have not been extensively studied. The aim of this study was to investigate the factors of pancreatic atrophy after gastric cancer surgery and to assess the effect of atrophy on BMI and quality of life, in order to promote postoperative management of patients with higher risk factors of pancreatic atrophy. Clinical data pertaining to 142 patients who underwent surgery for gastric cancer were retrospectively collected, and pancreatic volume was determined using abdominal computed tomography data. Influencing factors of pancreatic atrophy were analysed and the relationship of pancreatic atrophy to BMI and quality of life was measured. Correlation analysis using Pearson or Spearman rank correlation and multiple linear regression were used to analyse the risk factors influencing pancreatic atrophy. Pancreatic atrophy was significant in patients with gastric cancer 1 year after surgery, regardless of the surgical procedure. T3 and T4 stages, preoperative low levels of high-density lipoprotein cholesterol(HDL-C) and smoking history were influencing factors of pancreatic atrophy. Pancreatic atrophy was associated with reduced BMI and deterioration of quality of life. Clinicians need to monitor pancreatic function, BMI and life quality more carefully in gastric cancer patients with T3 and T4 stages, preoperative low levels of HDL-C and smoking history.
- 30 March 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-10
Open AccessPancreatic atrophy after gastric cancer surgery: influencing factors and effects on BMI and quality of life
Pancreatic atrophy can occur after gastric cancer surgery, but the influencing factors and effects of pancreatic atrophy have not been extensively studied. The aim of this study was to investigate the factors of pancreatic atrophy after gastric cancer surgery and to assess the effect of atrophy on BMI and quality of life, in order to promote postoperative management of patients with higher risk factors of pancreatic atrophy. Clinical data pertaining to 142 patients who underwent surgery for gastric cancer were retrospectively collected, and pancreatic volume was determined using abdominal computed tomography data. Influencing factors of pancreatic atrophy were analysed and the relationship of pancreatic atrophy to BMI and quality of life was measured. Correlation analysis using Pearson or Spearman rank correlation and multiple linear regression were used to analyse the risk factors influencing pancreatic atrophy. Pancreatic atrophy was significant in patients with gastric cancer 1 year after surgery, regardless of the surgical procedure. T3 and T4 stages, preoperative low levels of high-density lipoprotein cholesterol(HDL-C) and smoking history were influencing factors of pancreatic atrophy. Pancreatic atrophy was associated with reduced BMI and deterioration of quality of life. Clinicians need to monitor pancreatic function, BMI and life quality more carefully in gastric cancer patients with T3 and T4 stages, preoperative low levels of HDL-C and smoking history.